Sanjiv.Parant.

Which are the latest news on Sanjiv.Parant.?

How big is Sanjiv.Parant.?

As of 10th June, Sanjivani Paranteral Ltd has a market capitalization of 184.00 Cr and reported net sales of 68.66 Cr and net profit of 6.70 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Sanjivani Paranteral Ltd has a market capitalization of 184.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 68.66 Cr, while the sum of Net Profit for the same period is 6.70 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 38.00 Cr, and Total Assets amount to 78.20 Cr.

Who are in the management team of Sanjiv.Parant.?

The management team of Sanjiv.Parant. includes Ashwin Khemka (Chairman & Managing Director), Mrunmai M Sarvankar, Shrenikkumar P Solanki, and Monika Singhania (Independent Directors), Srivardhan Ashwani Khemka (Director), and Ritu Puglia (Company Secretary & Compliance Officer).

The management team of Sanjiv.Parant. includes the following individuals:<BR><BR>1. Ashwin Khemka - Chairman & Managing Director<BR>2. Mrunmai M Sarvankar - Independent Director<BR>3. Shrenikkumar P Solanki - Independent Director<BR>4. Monika Singhania - Independent Director<BR>5. Srivardhan Ashwani Khemka - Director<BR>6. Ritu Puglia - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its management, feel free to ask!

Should I buy, sell or hold Sanjivani Paranteral Ltd?

Why is Sanjivani Paranteral Ltd falling/rising?

As of 10-Jun, Sanjivani Paranteral Ltd's stock price is at 140.00, down 6.67%, and has significantly underperformed against the Sensex. The stock shows a consistent downward trend with a year-to-date decline of 39.54% and diminished investor participation.

As of 10-Jun, Sanjivani Paranteral Ltd's stock price is falling, currently at 140.00, which reflects a decrease of 10.0 or 6.67%. The stock has underperformed compared to the benchmark Sensex, which only declined by 0.49% over the same period. Over the past week, the stock has decreased by 2.57%, and its performance over the last month shows a significant drop of 14.27%. Year-to-date, the stock has fallen by 39.54%, and over the past year, it has decreased by 42.85%, indicating a consistent downward trend.<BR><BR>Today's trading activity further highlights the stock's decline, as it reached an intraday low of Rs 138.3, marking a 7.8% drop. The weighted average price suggests that more volume was traded closer to this low price, indicating a lack of investor confidence. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bearish trend. <BR><BR>Investor participation has also diminished, with delivery volume on June 9 falling by 96.59% compared to the 5-day average, suggesting that fewer investors are willing to hold the stock. Overall, these factors contribute to the stock's decline, reflecting a challenging environment for Sanjivani Paranteral Ltd.

What does Sanjiv.Parant. do?

Sanjivani Paranteral Ltd is a WHO-GMP certified pharmaceutical company specializing in injectables and oral solids, with a market cap of INR 184 Cr and reported net sales of 13 Cr and net profit of 1 Cr for March 2026. The company has over 25 years of experience in the Pharmaceuticals & Biotechnology industry.

Overview:<BR>Sanjivani Paranteral Ltd is a WHO-GMP certified pharmaceutical company specializing in the manufacturing of injectables and oral solids, operating within the Micro Cap market in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>The company was incorporated as a public limited company in October and has over two-and-a-half decades of experience. The latest reported quarterly results indicate net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 13 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 184 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 26.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.33%<BR>- Debt-Equity: 0.27<BR>- Return on Equity: 13.89%<BR>- Price to Book: 3.82<BR><BR>Contact Details:<BR>Address: 205 P N Khotari Indl Estate, LBS Marg Bhandup (West) Mumbai Maharashtra : 400078<BR>Tel: 91-22-67290900<BR>Email: info@sanjivani.co.in<BR>Website: http://www.sanjivani.co.in

Are Sanjivani Paranteral Ltd latest results good or bad?

Sanjivani Paranteral Ltd's latest results are concerning, showing a 74.89% decline in net profit and a 27.34% drop in revenue year-on-year for Q4 FY26, alongside a significant compression in profit margins and a high effective tax rate. Overall, these results indicate serious operational challenges and investor apprehension about the company's future.

The latest results for Sanjivani Paranteral Ltd indicate a challenging situation for the company. In Q4 FY26, the company reported a net profit of ₹0.55 crores, which represents a dramatic decline of 74.89% year-on-year. Revenue also fell significantly, down 27.34% year-on-year to ₹13.21 crores, and experienced a sharp 40.12% decline compared to the previous quarter.<BR><BR>The company's profit after tax (PAT) margin has compressed to 4.16%, down from 12.05% in the same quarter last year, highlighting serious operational issues. Additionally, the effective tax rate surged to an unusually high 54.17%, which has further impacted profitability without clear explanation.<BR><BR>While the company has shown robust growth in revenue for the full year FY25, reaching ₹70 crores, the fourth quarter results raise significant concerns about its operational execution and market demand. The stock has also faced a severe correction, trading significantly below its previous highs, which reflects investor apprehension regarding the sustainability of its business model.<BR><BR>Overall, the latest results can be characterized as bad, with notable declines in both profit and revenue, alongside troubling operational challenges that investors should closely monitor.

When is the next results date for Sanjivani Paranteral Ltd?

The next results date for Sanjivani Paranteral Ltd is 14 May 2026.

The next results date for Sanjivani Paranteral Ltd is scheduled for 14 May 2026.

Is Sanjiv.Parant. overvalued or undervalued?

As of November 17, 2025, Sanjiv.Parant. is considered very expensive and overvalued due to its high PE ratio of 30.96, price to book value of 6.08, and EV to EBITDA of 23.36, especially in light of its 37.72% decline in stock performance compared to the Sensex's 9.50% gain over the past year.

As of 17 November 2025, the valuation grade for Sanjiv.Parant. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued based on its high PE ratio of 30.96, a price to book value of 6.08, and an EV to EBITDA of 23.36. In comparison to its peers, Sun Pharma has a higher PE ratio of 36.69, while Cipla appears more attractive with a PE of 22.81.<BR><BR>Given these ratios and the overall market context, Sanjiv.Parant.'s valuation seems excessive, particularly when considering its recent stock performance, which has underperformed the Sensex significantly over the past year, with a decline of 37.72% compared to the Sensex's gain of 9.50%. This further reinforces the conclusion that the company is overvalued in its current state.

How has been the historical performance of Sanjiv.Parant.?

Sanjiv.Parant. experienced significant growth from March 2024 to March 2025, with net sales rising to 70.10 Cr from 54.41 Cr, and profit after tax increasing to 8.09 Cr from 6.17 Cr. The company also saw improvements in operating profit and cash flow from operating activities, alongside a rise in total assets and liabilities.

Answer:<BR>The historical performance of Sanjiv.Parant. shows significant growth from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Sanjiv.Parant. reported net sales of 70.10 Cr, an increase from 54.41 Cr in the previous year. Total operating income also rose to 70.10 Cr from 54.41 Cr, while total expenditure increased to 59.75 Cr from 46.17 Cr. The operating profit (PBDIT) grew to 11.57 Cr from 8.76 Cr, reflecting a healthy operating profit margin of 14.76%, slightly down from 15.14%. Profit before tax reached 10.35 Cr, up from 7.57 Cr, leading to a profit after tax of 8.09 Cr compared to 6.17 Cr the prior year. The earnings per share improved to 6.81 from 5.28. On the balance sheet, total assets increased to 78.20 Cr from 43.41 Cr, with total liabilities also rising to 78.20 Cr from 43.41 Cr. Cash flow from operating activities improved to 12.00 Cr from -10.00 Cr, while cash flow from investing activities worsened to -21.00 Cr from -12.00 Cr. Overall, the company demonstrated strong growth in sales and profitability, alongside a notable increase in total assets and liabilities.

What is the technical trend for Sanjiv.Parant.?

As of May 28, 2025, the technical outlook for Sanjiv.Parant. is mildly bearish, with mixed signals from MACD, moving averages, and Bollinger Bands, and a year-to-date decline of 36.13% compared to the Sensex's gain of 5.48%.

As of 28 May 2025, the technical trend for Sanjiv.Parant. has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The daily moving averages also reflect a mildly bearish stance. Bollinger Bands show a mildly bearish trend on the weekly chart but are bullish on the monthly chart, suggesting mixed signals across time frames. The KST is bearish weekly and mildly bearish monthly, further supporting the overall mildly bearish outlook. The stock has underperformed the Sensex in the year-to-date period, with a significant decline of 36.13%, contrasting with the Sensex's gain of 5.48%. Overall, the current technical stance is mildly bearish, with key indicators such as MACD and moving averages driving this view.

Who are the top shareholders of the Sanjiv.Parant.?

The top shareholders of Sanjiv.Parant. are Ashwani Khemka with 27.13%, and Suresh Pukhraj Jain, the highest public shareholder, with 6.63%. Individual investors hold a combined 52.43%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Sanjiv.Parant. include Ashwani Khemka, who holds the largest share at 27.13%. The highest public shareholder is Suresh Pukhraj Jain, with a holding of 6.63%. Additionally, individual investors collectively hold 52.43% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Has Sanjiv.Parant. declared dividend?

No Dividend History Available

Who are the peers of the Sanjiv.Parant.?

Sanjiv.Parant.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ambalal Sarabhai, Coral Labs, Kimia Bioscien, and Sat Kartar. Notably, Sanjiv.Parant. has excellent management and growth, with a 1-year return of 33.70%.

Peers: The peers of Sanjiv.Parant. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ambalal Sarabhai, Coral Labs., Kimia Bioscien., Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Sanjiv.Parant., while Below Average management risk is found at Ambalal Sarabhai, Coral Labs., Kimia Bioscien., and Sat Kartar. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Sanjiv.Parant., while Below Average growth is noted for Divi's Lab., Torrent Pharma, Ambalal Sarabhai, and Kimia Bioscien. Average capital structure is found at Sanjiv.Parant., while Excellent capital structure is observed at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, and Good capital structure is noted for Torrent Pharma and Ambalal Sarabhai.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ambalal Sarabhai has the lowest at -21.20%. Sanjiv.Parant.'s 1-year return of 33.70% is higher than Ambalal Sarabhai's but lower than Divi's Lab.'s. Additionally, the six-month returns for Ambalal Sarabhai, Coral Labs., and Kimia Bioscien. are negative.